Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SCNX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The Chief Financial Officer resigned from the company effective May 26, 2026.
Scienture CFO Eric Sherb resigns; Co-CEO Dr. Mani assumes interim financial role
Filed May 29, 2026 · Period ending May 26, 2026 · ~1 min read
Key Changes
-
high
CFO Eric Sherb resigned effective May 26, 2026, citing personal reasons with no dispute with management or the board.
Item 5.02 verify on EDGAR → -
high
Co-CEO Dr. Narasimhan Mani appointed Interim CFO while retaining his existing executive roles as Co-CEO and President.
Item 5.02 verify on EDGAR → -
medium
Dr. Mani brings 25+ years pharmaceutical experience, prior financial leadership roles at life sciences companies, and an MBA in Finance from Columbia Business School.
Item 5.02 verify on EDGAR →
Summary
Scienture Holdings disclosed the sudden departure of CFO Eric Sherb on May 26, 2026, who resigned for personal reasons with no stated disagreement with management. The company immediately filled the gap by appointing Co-CEO Dr. Narasimhan Mani as Interim CFO, adding financial oversight to his existing executive responsibilities. While the company emphasizes Dr.
Mani's financial credentials—including an MBA from Columbia and prior finance roles at Johnson & Johnson and Amneal Pharmaceuticals—retail investors should note the concentration of executive power in one individual now serving as both Co-CEO and CFO. This dual role may raise governance questions, particularly during the interim period.
Investors should watch for the company's timeline to recruit a permanent CFO and monitor upcoming financial filings for any changes in reporting quality or internal controls during this leadership transition. The next quarterly earnings report will be the first test of the new financial leadership structure.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 26, 2026, Eric Sherb, the Chief Financial Officer (“CFO”) of Scienture Holdings, Inc. (the “Company”), formally resigned his position as CFO and advised the Company that his resignation was due to personal reasons and not a result of any dispute or disagreement with the Company, its management, or its board of directors.
Eric Sherb resigned as Chief Financial Officer effective May 26, 2026. The company stated his departure was for personal reasons and not due to any dispute with management or the board. This is a key leadership change affecting the company's financial oversight.
Added in current filing · verify on EDGAR →
In connection with Mr. Sherb’s resignation, the Company appointed Dr. Narasimhan Mani (age 51) to serve as the Company’s Interim Chief Financial Officer (“Interim CFO”) effective as of May 26, 2026. Dr. Mani has served as a director and the Co-Chief Executive Officer and President of the Company since May 2025.
Dr. Narasimhan Mani, currently serving as Co-CEO and President since May 2025, was appointed Interim CFO effective May 26, 2026. He will assume CFO responsibilities while continuing his existing executive roles. The company notes he has overseen financial operations including revenue and expense management, financial planning and analysis, and financial reporting.
Added in current filing · verify on EDGAR →
Dr. Mani is an experienced healthcare professional, having been employed in the pharmaceutical industry for over 25 years with many of those in senior management positions. In addition to Dr. Mani’s technical pharmaceutical experience, he has served in various financial-focused roles for life sciences companies and holds an MBA in Finance and Marketing from Columbia Business School.
The company disclosed Dr. Mani's background to support his CFO appointment. He has 25+ years in pharmaceuticals including senior management roles, has held financial-focused positions at life sciences companies, and holds an MBA in Finance and Marketing from Columbia Business School. His prior roles include CEO positions at Kesin Pharma and Xiromed, VP of Global Corporate Strategy at Amneal Pharmaceuticals, and Corporate Finance leader at Johnson & Johnson.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 29, 2026 · How we verify